This invention relates to compounds, which are generally anti-inflammatory and analgesic compounds, and which are represented by Formula I:
1
wherein A is a —CH
2
—, —O—, —S—, or —S(O)—; and the other substituents are as defined in the specification; or individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents
Process for producing 6-aminomethyl-substituted quinoline-benzoic acids
申请人:ASAHI GLASS COMPANY LTD.
公开号:EP0763536A1
公开(公告)日:1997-03-19
6-Aminomethyl-substituted quinolinebenzoic acids useful as angiotensin II antagonists are easily produced in a short step. A 2-6-(halomethyl)quinolin-2-yl}benzoic acid (1) is reacted with a secondary amine such as a 3H-imidazo[4,5-b]pyridine (2) in the presence of a base to thereby produce a 6-aminomethyl-substituted quinolinebenzoic acid (4) wherein Z may be a bromine atom, etc., R1 to R3 each may be an alkyl group, etc. and X and Y may be =N or =CH.
Carbocyclic and nitrogen-containing fused CH-acids with an annelated indenyl fragment. Thermogravimetric and X-ray structural analysis of 6H-indeno[1,2-b]quinoline
作者:V. G. Pleshakov、V. M. Akimov、E. Huipe Nava、S. V. Lindeman、Yu. T. Struchkov、K. D. Ambacheu、A. G. Dudareva、M. A. Ryashentseva、V. P. Zvolinsky、N. S. Prostakov
DOI:10.1007/bf00698503
日期:1995.4
Based on thermogravimetric characteristics first obtained for the model 6H-indeno [1,2-b]quinoline, the scheme of thermal conversions of this compound in the temperature range 20–700 °C has been proposed, and the limit of its thermal stability (∼300 °C) has been determined. This temperature is recommended as the optimum for synthesizing fused benzoaza(diaza)fluorenes. Based on the results of X-ray
[EN] INDOLE DERIVATIVES AS COX II INHIBITORS<br/>[FR] DERIVES D'INDOLE UTILES COMME INHIBITEURS DE COX II
申请人:HOFFMANN LA ROCHE
公开号:WO2003029212A1
公开(公告)日:2003-04-10
This present invention relates to indole derivatives of Formula (I); wherein A, Ar and R1 to R4 are as defines in the specification. The compounds are useful as a selective COX-II inhibitor and, therefore, may be used for the treatment of COX-II mediated diseases.